The aim of this study was to compare the effects of 3 different statin regimens that have equivalent low-density lipoprotein cholesterol (LDL-C) lowering efficacy on the apolipoprotein B/A1 ratio and glucose metabolism. After a 4-week dietary lead-in, 90 hypercholeserolemic patients were randomly assigned to 1 of 3 treatment groups for 8 weeks: atorvastatin 20 mg, rosuvastatin 10 mg, or atorvastatin/ezetimibe 5 mg/5 mg. At drug treatment week 8, we compared the percentage changes in lipid parameters, apolipoprotein B/A1 ratio, hemoglobin A1c, and homeostasis model assessment-insulin resistance (HOMA-IR) from baseline. Seventy-six patients completed the study and the percentage changes in LDL-C were comparable among the groups. However, the percentage reduction in the apolipoprotein B/A1 ratio was significantly greater in the rosuvastatin group (—47% ± 14%, P = .04) and the combination group (—46% ± 8%, P = .05) than in the atorvastatin group (—39% ± 11%). The percentage increase in hemoglobin A1c was small but significantly greater in the atorvastatin group compared to the combination group (3.0% ± 5.2% and —0.4% ± 4.0%, P = .03). The effect of rosuvastatin on hemoglobin A1c was not different from those of the other 2 regimens. The effects of 3 statin regimens were similar on HOMA-IR. In conclusion, 3 statin regimens have differential effect on apolipoprotein B/A1 and glycemic control after comparable LDL-C reduction.
Sager PT, Capece R., Lipka L., et al. Effects of ezetimibe coadministered with simvastatin on C-reactive protein in a large cohort of hypercholesterolemic patients. Atherosclerosis. 2005;179(2): 361-367.
2.
Rizzo M., Berneis K.The clinical relevance of low-density-lipoprotein size modulation by statins . Cardiovasc Drugs Ther. 2006;20(3):205-217.
3.
Sasaki J., Iwashita M., Kono S.Statins: beneficial or adverse for glucose metabolism. J Atheroscler Thromb. 2006;13(3):123-129.
4.
Wolffenbuttel BH, Franken AA, Vincent HH and the Dutch Corall Study Group. Cholesterol-lowering effects of rosuvastatin compared with atorvastatin in patients with type 2 diabetes-CORALL study. J Intern Med. 2005;257(6):531-539.
5.
Freeman DJ, Norrie J., Sattar N., et al. Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation. 2001;103(3):357-362.
6.
Ridker PM, Danielson E., Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21):2195-2207.
7.
Walldius G., Jungner I., Holme I., Aastveit AH, Koar W., Steinder E.High apolipoprotein B, low apolipoprotein A-1, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet. 2001;358(9298):2026-2033.
8.
Benn M., Nordestgaard B., Jensen G., Tybjaerg-Hansen A.Improving prediction of ischemic cardiovascular disease in the general population using apolipoprotein B: the Copenhagen City Heart Study. Arterioscler Thromb Vasc Biol. 2007;2(3)7:661-670.
9.
Feldman T., Koren M., Insull W. Jr, et al. Treatment of high-risk patients with ezetimibe plus simvastatin co-administration versus simvastatin alone to attain National Cholesterol Education Program Adult Treatment Panel III low-density lipoprotein cholesterol goals. Am J Cardiol. 2004;93(12):1481-1486.
10.
Ballantyne CM, Balzing MA, King TR, Brady WE, Palmisano J.Efficacy and safety of ezetimibe co-administered with simvastatin compared with atorvastatin in adults with hypercholesterolemia . Am J Cardiol. 2004;93(12):1487-1494.
11.
Stein E., Stender S., Mata P., et al. Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe co-administered with atorvastatin. Am Heart J. 2004;148(3):447-455.
12.
Tremblay AJ , Lamarche B., Cohn JS, Hogue JC, Couture P.Effect of ezetimibe on the in vivo kinetics of apob-48 and apob-100 in men with primary hypercholesterolemia. Arerioscler Thromb Vasc Biol. 2006;26(5):1101-1106.
13.
Kalogirou M. , Tsimihodimos V., Gazi I., et al. Effect of ezetimibe monotherapy on the concentration of lipoprotein subfractions in patients with primary dyslipidemia . Curr Med Res Opin. 2007;23(5):1169-1176.
14.
Denke M., Pearson T., McBride P., Gazzara RA, Brady WE, Tershakovec AMEzetimibe added to ongoing statin therapy improves LDL-C goal attainment and lipid profile in patients with diabetes or metabolic syndrome. Diab Vasc Dis Res. 2006;3(2):93-102.
15.
Piorkowski M., Fischer S., Stellbaum C., et al. Treatment with ezetimibe plus low-dose atorvastatin compared with higher-dose atorvastatin alone. J Am Coll Cardiol. 2007;49(10):1035-1042.
16.
Liu PY, Liu YW, Lin LJ, Chen JH, Liao JKEvidence for statin pleiotropy in humans: differential effects of statins and ezetimibe on Rho-associated coiled-coil containing protein kinase activity, endothelial function, and inflammation. Circulation.2009; 119(1):131-138.
17.
Deedwania PC , Hunninghake DB, Bays HE, Jones PH, Cain VA, Blasetto JW for the STELLAR Study Group. Effects of rosuvastatin, atorvastatin, simvastatin, pravastatin on atherogenic dyslipidemia in patients with characteristics of the metabolic syndrome. Am J Cardiol. 2005;95(3):360-366.
18.
Milionis HJ , Rizos E., Kostapanos M., et al. Treating to target patients with primary hyperlipidemia: comparison of the effects of atorvastatin and rosuvastatin (the ATOROS study). Curr Med Res Opin2006 ;22(6):1123-1131.
19.
Schwarz GG, Bolognese MA, Tremblay BP, et al. Efficacy and safety of rosuvastatin and atorvastatin in patients with hypercholesterolemia and a high risk of coronary heart disease: a randomized, controlled trial. Am Heart J.2004;148(1):e4.
20.
Freeman DJ, Norrie J., Sattar N., et al. Pravastatin and the development of diabetes mellitus evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation. 2001;103(3):357-362.
21.
Hear Protection Study Collaborative Group.MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebe-controlled trial. Lancet. 2002;360(9326):7-22.
22.
Sever PS, Dahlof B., Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentration, in the anglo-Scandinavian cardiac outcomes trial. Lipid lowering arm (ASCOT-LLA): a multicenter randomized controlled trialLancet. 2003;361(9364):1149-1158.
23.
Cannon CP, Braunwald E., McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004 ;350(15):1495-1504.
24.
Huptas S., Geiss HC, Otto C., Parhofer KGEffect of atorvastatin (10 mg/day) on glucose metabolism in patients with the metabolic syndrome. Am J Cardiol. 2006 ;98(1):66-69.
25.
Tanaka A., Yamada N., Saito Y., Kawakami M., Ohashi Y., Akanuma Y.A double-blind trial on the effects of atorvastatin on glycemic control in Japanese diabetic patients with hypercholesterolemia. Clin Chim Acta. 2001;312(1-2):41-47.
26.
Takano T., Yamakawa T., Takahashi M., Kimura M., Okamura A.Influences of statins on glucose tolerance in patients with type 2 diabetes mellitus. J Atheroscler Thromb. 2006;13(2):95-100.
27.
Sasaki J., Ikeda Y., Kuribayashi T., et al. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance . Clin Ther. 2008;30(6):1089-1101.
28.
Yada T., Kakata M., Shiraishi T., Kakei M.Inhibition by simvastatin, but not pravastatin, of glucose-induced cytosolic Ca2+ signaling and insulin secretion due to blockage of L-type Ca2+ channels in rat islet b cells. Br J Pharmacol. 1999 ; 126(5):1205-1213.
29.
Ishikawa M. , Okajima F., Inoue N., et al. Distinct effects of pravastatin, atorvastatin, simvastatin on insulin secretion from a β-cell line, MIN6 cells. J Atheroscler Thromb. 2006;13(6): 329-335.
30.
Nakata M., Nagasaka S., Kusaka I., Matsuoka H., Ishibashi S., Yada T.Effects of statins on the adipocyte maturation and expression of glucose transporter 4 (SLC2A4): implications in glycemic control. Diabetologia . 2006;49(8):1881-1892.
31.
Dagli N., Yavuzkir M., Karaca I.The effects of high dose pravastatin and low dose pravastatin and ezetimibe combination therapy on lipid, glucose metabolism and inflammation. Inflammation. 2007;30(6):230-235.
32.
Naples M., Federico LM, Xu E., Nelken J., Adeli K.Effect of rosuvastatin on insulin sensitivity in an animal model of insulin resistance: evidence for statin-induced hepatic insulin sensitization. Atherosclerosis. 2008;198(1):94-103.
33.
Kostapanos MS, Milionis HJ, Agouridis AD, Rizos CV, Elisaf MSRosuvastatin treatment is associated with an increase in insulin resistance in hyperlipidemic patients with impaired fasting glucose. Int J Clin Pract.2009;63(9):1308-1313.
34.
Clearfield MB, Amerena J., Bassand JP, et al. Comparison of the efficacy and safety of rosuvastatin 10 mg and atorvastatin 20 mg in high-risk patients with hypercholesterolemia-prospective study to evaluate the use of low doses of the statins atorvastatin and rosuvastatin (PULSAR). Trials. 2006;7:35.
35.
Baruch L., Gupta B., Lieberman-Blum SS, Agarwal S., Eng C.Ezetimibe 5 and 10 mg for lowering LDL-C: potential billion-dollar savings with improved tolerability. Am J Manag Care. 2008;14(10):637-641.
36.
Kosoglou T. , Statkevich P., Meyer I., et al. Effects of ezetimibe on the pharmacodynamics and pharmacokinetics of lovastatin. Curr Med Res Opin. 2004;20(6):955-965.
